Study of an experimental drug for early Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tests an investigational drug, ARO-MAPT-SC, which targets a protein involved in Alzheimer's disease. It is for people with early Alzheimer's to see if the drug is safe and can slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 50 and 80 years old and have been diagnosed with early Alzheimer's disease.
- You need a trusted family member or friend who can come to study visits and talk with the research team about you.
- You cannot be pregnant or nursing, and must use effective birth control during the study and for 3 months after.
- You must be generally healthy aside from Alzheimer's, without serious heart, liver, kidney, or infectious diseases like HIV or hepatitis.
- You must be willing to have a lumbar puncture (spinal tap) and have blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This study tests new treatments that target amyloid plaques in the brain, which are linked to Alzheimer's disease. It includes both healthy people and those with mild cognitive impairment or mild-to-moderate Alzheimer's, to see if the treatments are safe and how they affect the body.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
Hear when a new Alzheimer Disease, Early Onset trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.